Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 5, 2011, Pages 948-964

  MacLennan, David H ^a   Zvaritch, Elena ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Calcium; Calsequestrin; Catecholaminergic polymorphic ventricular tachycardia; Central core disease; Malignant hyperthermia; Ryanodine receptor

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; CALSEQUESTRIN; DANTROLENE; RYANODINE RECEPTOR;

BINDING AFFINITY; CALCIUM BINDING; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CENTRAL CORE DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HISTOCHEMISTRY; HUMAN; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE;

ANIMALS; CALCIUM SIGNALING; HUMANS; MODELS, BIOLOGICAL; MUSCULAR DISEASES; MUTATION; PENETRANCE; SARCOPLASMIC RETICULUM;

EID: 79955659959     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.11.009     Document Type: Review

References (237)

1. Zubrzycka E., MacLennan D.H. Assembly of the sarcoplasmic reticulum. Biosynthesis of calsequestrin in rat skeletal muscle cell cultures. J. Biol. Chem. 1976, 251:7733-7738.
2. Zubrzycka-Gaarn E.E., Bulman D.E., Karpati G., Burghes A.H., Belfall B., Klamut H.J., Talbot J., Hodges R.S., Ray P.N., Worton R.G. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988, 333:466-469.
3. Zubrzycka-Gaarn E.E., Hutter O.F., Karpati G., Klamut H.J., Bulman D.E., Hodges R.S., Worton R.G., Ray P.N. Dystrophin is tightly associated with the sarcolemma of mammalian skeletal muscle fibers. Exp. Cell Res. 1991, 192:278-288.
4. Fliegel L., Burns K., MacLennan D.H., Reithmeier R.A., Michalak M. Molecular cloning of the high affinity calcium-binding protein (calreticulin) of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 1989, 264:21522-21528.
5. Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., Krause K.H., Opas M., MacLennan D.H., Michalak M. Calreticulin is essential for cardiac development. J. Cell Biol. 1999, 144:857-868.
6. 2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature 1985, 316:696-700.
7. 2+-ATPase gene. J. Biol. Chem. 1988, 263:4813-4819.
8. Denborough M.A., Lovell R.R.H. Anesthetic deaths in a family. Lancet 1960, 2:45.
9. Denborough M.A., Forster J.F., Lovell R.R., Maplestone P.A., Villiers J.D. Anaesthetic deaths in a family. Br. J. Anaesth. 1962, 34:395-396.
10. Denborough M.A., Hird F.J., King J.O. Malignant hyperpyrexia. Br. Med. J. 1971, 3:636-637.
11. Britt B.A. Malignant hyperthermia: a review. Thermoregulation: Pathology, Pharmacology and Therapy 1991, 179-292. Pergamon Press, New York. E. Schonbaum, P. Lomax (Eds.).
12. Rosenberg H., Davis M., James D., Pollock N., Stowell K. Malignant hyperthermia. Orphanet J. Rare Dis. 2007, 2:21.
13. Britt B.A., Kalow W. Malignant hyperthermia: a statistical review. Can. Anaesth. Soc. 1970, 17:293-315.
14. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth. Analg. 1985, 64:700-704.
15. Monnier N., Krivosic-Horber R., Payen J.F., Kozak-Ribbens G., Nivoche Y., Adnet P., Reyford H., Lunardi J. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002, 97:1067-1074.
16. MacLennan D.H., Phillips M.S. Malignant hyperthermia. Science 1992, 256:789-794.
17. Robinson R., Carpenter D., Shaw M.A., Halsall J., Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum. Mutat. 2006, 27:977-989.
18. Monnier N., Procaccio V., Stieglitz P., Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the α1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am. J. Hum. Genet. 1997, 60:1316-1325.
19. Stewart S.L., Hogan K., Rosenberg H., Fletcher J.E. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin. Genet. 2001, 59:178-184.
20. Carpenter D., Ringrose C., Leo V., Morris A., Robinson R.L., Halsall P.J., Hopkins P.M., Shaw M.A. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med. Genet. 2009, 10:104.
21. Pirone A., Schredelseker J., Tuluc P., Gravino E., Fortunato G., Flucher B.E., Carsana A., Salvatore F., Grabner M. Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the CaV α1S subunit. Am. J. Physiol. Cell Physiol. 2010, 299:C1345-1354.
22. Toppin P.J., Chandy T.T., Ghanekar A., Kraeva N., Beattie W.S., Riazi S. A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene. Can. J. Anaesth. 2010, 57:689-693.
23. Wappler F., Fiege M., Steinfath M., Agarwal K., Scholz J., Singh S., Matschke J., Schulte Am Esch J. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001, 94:95-100.
24. Larach M.G., Gronert G.A., Allen G.C., Brandom B.W., Lehman E.B. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth. Analg. 2010, 110:498-507.
25. Krause T., Gerbershagen M.U., Fiege M., Weisshorn R., Wappler F. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004, 59:364-373.
26. Rosero E.B., Adesanya A.O., Timaran C.H., Joshi G.P. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009, 110:89-94.
27. Brandom B.W. Ambulatory surgery and malignant hyperthermia. Curr. Opin. Anaesthesiol. 2009, 22:744-747.
28. Shy G., Magee K. A new congenital non-progressive myopathy. Brain 1956, 102:581-594.
29. Jungbluth H. Central core disease. Orphanet J. Rare Dis. 2007, 2:25.
30. Shuaib A., Paasuke R.T., Brownell K.W. Central core disease. Clinical features in 13 patients. J. Comp. Pathol. 1987, 97:597-600.
31. De Cauwer H., Heytens L., Martin J.J. Workshop report of the 89th ENMC International Workshop: Central Core Disease, 19th-20th January 2001, Hilversum, The Netherlands. Neuromuscul. Disord. 2002, 12:588-595.
32. Dubowitz V., Pearse A.G. Oxidative enzymes and phosphorylase in central-core disease of muscle. Lancet 1960, 2:23-24.
33. Engel W.K. Muscle target fibres, a newly recognized sign of denervation. Nature 1961, 191:389-390.
34. Seitelberger F., Wanko T., Gavin M.A. The muscle fiber in central core disease. Histochemical and electron microscopic observations. Acta Neuropathol. 1961, 1:223-237.
35. Gonatas N.K., Perez M.C., Shy G.M., Evangelista I. Central "core" disease of skeletal muscle. Ultrastructural and cytochemical observations in two cases. Am. J. Pathol. 1965, 47:503-524.
36. Denborough M.A., Dennett X., Anderson R.M. Central-core disease and malignant hyperpyrexia. Br. Med. J. 1973, 1:272-273.
37. 2+ release channels. Am. J. Med. 1998, 104:470-486.
38. Quane K.A., Keating K.E., Healy J.M., Manning B.M., Krivosic-Horber R., Krivosic I., Monnier N., Lunardi J., McCarthy T.V. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 1994, 23:236-239.
39. Guis S., Figarella-Branger D., Monnier N., Bendahan D., Kozak-Ribbens G., Mattei J.P., Lunardi J., Cozzone P.J., Pellissier J.F. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch. Neurol. 2004, 61:106-113.
40. Monnier N., Kozak-Ribbens G., Krivosic-Horber R., Nivoche Y., Qi D., Kraev N., Loke J., Sharma P., Tegazzin V., Figarella-Branger D., Romero N., Mezin P., Bendahan D., Payen J.F., Depret T., Maclennan D.H., Lunardi J. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum. Mutat. 2005, 26:413-425.
41. Sharma M.C., Jain D., Sarkar C., Goebel H.H. Congenital myopathies - a comprehensive update of recent advancements. Acta Neurol. Scand. 2009, 119:281-292.
42. Schmitt H.P., Volk B. The relationship between target, targetoid, and targetoid/core fibers in severe neurogenic muscular atrophy. J. Neurol. 1975, 210:167-181.
43. Gullotta F., Pavone L., La Rosa M., Grasso A. Minicore myopathy. Klin. Wochenschr. 1982, 60:1351-1355.
44. Newham D.J., McPhail G., Mills K.R., Edwards R.H. Ultrastructural changes after concentric and eccentric contractions of human muscle. J. Neurol. Sci. 1983, 61:109-122.
45. Jungbluth H. Multi-minicore disease. Orphanet J. Rare Dis. 2007, 2:31.
46. Monnier N., Ferreiro A., Marty I., Labarre-Vila A., Mezin P., Lunardi J. A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. Hum. Mol. Genet. 2003, 12:1171-1178.
47. Monnier N., Romero N.B., Lerale J., Nivoche Y., Qi D., MacLennan D.H., Fardeau M., Lunardi J. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum. Mol. Genet. 2000, 9:2599-2608.
48. Scacheri P.C., Hoffman E.P., Fratkin J.D., Semino-Mora C., Senchak A., Davis M.R., Laing N.G., Vedanarayanan V., Subramony S.H. A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy. Neurology 2000, 55:1689-1696.
49. Jungbluth H., Zhou H., Sewry C.A., Robb S., Treves S., Bitoun M., Guicheney P., Buj-Bello A., Bonnemann C., Muntoni F. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul. Disord. 2007, 17:338-345.
50. Sato I., Wu S., Ibarra M.C., Hayashi Y.K., Fujita H., Tojo M., Oh S.J., Nonaka I., Noguchi S., Nishino I. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology 2008, 70:114-122.
51. Clarke N.F., Waddell L.B., Cooper S.T., Perry M., Smith R.L., Kornberg A.J., Muntoni F., Lillis S., Straub V., Bushby K., Guglieri M., King M.D., Farrell M.A., Marty I., Lunardi J., Monnier N., North K.N. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum. Mutat. 2010, 31:E1544-E1550.
52. Coumel P., Fidelle J., Lucet V., Attuel P., Bouvrain Y. Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. Br. Heart J. 1978, 40:28-37.
53. Leenhardt A., Lucet V., Denjoy I., Grau F., Ngoc D.D., Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995, 91:1512-1519.
54. Hayashi M., Denjoy I., Extramiana F., Maltret A., Buisson N.R., Lupoglazoff J.M., Klug D., Hayashi M., Takatsuki S., Villain E., Kamblock J., Messali A., Guicheney P., Lunardi J., Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009, 119:2426-2434.
55. Priori S.G., Napolitano C., Memmi M., Colombi B., Drago F., Gasparini M., DeSimone L., Coltorti F., Bloise R., Keegan R., Cruz Filho F.E., Vignati G., Benatar A., DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106:69-74.
56. Tester D.J., Spoon D.B., Valdivia H.H., Makielski J.C., Ackerman M.J. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin. Proc. 2004, 79:1380-1384.
57. Priori S.G., Napolitano C., Tiso N., Memmi M., Vignati G., Bloise R., Sorrentino V., Danieli G.A. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001, 103:196-200.
58. Katz G., Arad M., Eldar M. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr. Probl. Cardiol. 2009, 34:9-43.
59. Swan H., Piippo K., Viitasalo M., Heikkila P., Paavonen T., Kainulainen K., Kere J., Keto P., Kontula K., Toivonen L. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J. Am. Coll. Cardiol. 1999, 34:2035-2042.
60. Lahat H., Pras E., Olender T., Avidan N., Ben-Asher E., Man O., Levy-Nissenbaum E., Khoury A., Lorber A., Goldman B., Lancet D., Eldar M. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am. J. Hum. Genet. 2001, 69:1378-1384.
61. 2+ handling and causes complex ventricular arrhythmias in mice. Cardiovasc. Res. 2007, 75:69-78.
62. 2+ release, and catecholaminergic polymorphic ventricular tachycardia. J. Clin. Invest. 2006, 116:2510-2520.
63. di Barletta M.R., Viatchenko-Karpinski S., Nori A., Memmi M., Terentyev D., Turcato F., Valle G., Rizzi N., Napolitano C., Gyorke S., Volpe P., Priori S.G. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006, 114:1012-1019.
64. Rizzi N., Liu N., Napolitano C., Nori A., Turcato F., Colombi B., Bicciato S., Arcelli D., Spedito A., Scelsi M., Villani L., Esposito G., Boncompagni S., Protasi F., Volpe P., Priori S.G. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ. Res. 2008, 103:298-306.
65. Song L., Alcalai R., Arad M., Wolf C.M., Toka O., Conner D.A., Berul C.I., Eldar M., Seidman C.E., Seidman J.G. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J. Clin. Invest. 2007, 117:1814-1823.
66. Blayney L.M., Lai F.A. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol. Ther. 2009, 123:151-177.
67. Yano M. Ryanodine receptor as a new therapeutic target of heart failure and lethal arrhythmia. Circ. J. 2008, 72:509-514.
68. Britt B.A., Locher W.G., Kalow W. Hereditary aspects of malignant hyperthermia. Can. Anaesth. Soc. J. 1969, 16:89-98.
69. Engel W.K., Foster J.B., Hughes B.P., Huxley H.E., Mahler R. Central core disease - an investigation of a rare muscle cell abnormality. Brain 1961, 84:167-185.
70. Weber A. On the role of calcium in the activity of adenosine 5'-triphosphate hydrolysis by actomyosin. J. Biol. Chem. 1959, 234:2764-2769.
71. Ebashi S. Calcium binding and relaxation in the actomyosin system. J. Biochem. 1960, 48:150-151.
72. Weber A., Winicur S. The role of calcium in the superprecipitation of actomyosin. J. Biol. Chem. 1961, 236:3198-3202.
73. Ebashi S. Calcium binding activity of vesicular relaxing factor. J. Chir. (Paris) 1961, 50:236-244.
74. Ebashi S., Lipman F. Adenosine triphosphate-linked concentration of calcium ions in a particulate fraction of rabbit muscle. J. Cell Biol. 1962, 14:389-400.
75. Ebashi F., Ebashi S. Removal of calcium and relaxation in actomyosin systems. Nature 1962, 194:378-379.
76. Ebashi S., Endo M., Otsuki I. Control of muscle contraction. Q. Rev. Biophys. 1969, 2:351-384.
77. Zot A.S., Potter J.D. Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction. Annu. Rev. Biophys. Biophys. Chem. 1987, 16:535-559.
78. Walsh D.A., Perkins J.P., Krebs E.G. An adenosine 3', 5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. J. Biol. Chem. 1968, 243:3763-3765.
79. Brostrom C.O., Corbin J.D., King C.A., Krebs E.G. Interaction of the subunits of adenosine 3':5'-cyclic monophosphate-dependent protein kinase of muscle. Proc. Natl Acad. Sci. USA 1971, 68:2444-2447.
80. Furuya E., Yokoyama M., Uyeda K. Regulation of fructose-6-phosphate 2-kinase by phosphorylation and dephosphorylation: possible mechanism for coordinated control of glycolysis and glycogenolysis. Proc. Natl Acad. Sci. USA 1982, 79:325-329.
81. Hall L.W., Woolf N., Bradley J.W., Jolly D.W. Unusual reaction to suxamethonium chloride. Br. Med. J. 1966, 2:1305.
82. Harrison G.G., Biebuyck J.F., Terblanche J., Dent D.M., Hickman R., Saunders S.J. Hyperpyrexia during anaesthesia. Br. Med. J. 1968, 3:594-595.
83. Harrison G.G. Porcine malignant hyperthermia. Int. Anesthesiol. Clin. 1979, 17:25-61.
84. Harrison G.G. Pale, soft exudative pork, porcine stress syndrome and malignant hyperpyrexia - an identity?. J. S. Afr. Vet. Assoc. 1972, 43:57-63.
85. Muir A.R. Normal and regenerating skeletal muscle fibres in Pietrain pigs. J. Comp. Pathol. 1970, 80:137-143.
86. Denborough M.A. The pathopharmacology of malignant hyperpyrexia. Pharmacol. Ther. 1980, 9:357-365.
87. Berman M.C., Harrison G.G., Bull A.B., Kench J.E. Changes underlying halothane-induced malignant hyperpyrexia in Landrace pigs. Nature 1970, 225:653-655.
88. Hasselbach W., Makinose M. ATP and active transport. Biochem. Biophys. Res. Commun. 1962, 7:132-136.
89. Hasselbach W. Relaxation and the sarcotubular calcium pump. Fed. Proc. 1964, 23:909-912.
90. Marsh B.B. A factor modifying muscle fibre synaeresis. Nature 1951, 167:1065-1066.
91. Weber A., Herz R. The relationship between caffeine contracture of intact muscle and the effect of caffeine on reticulum. J. Gen. Physiol. 1968, 52:750-759.
92. Herrmann-Frank A., Luttgau H.C., Stephenson D.G. Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story. J. Muscle Res. Cell Motil. 1999, 20:223-237.
93. Endo M., Tanaka M., Ogawa Y. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 1970, 228:34-36.
94. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am. J. Physiol. 1983, 245:C1-C14.
95. Kalow W., Britt B.A., Terreau M.E., Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970, 2:895-898.
96. Ellis F.R., Harriman D.G., Keaney N.P., Kyei-Mensah K., Tyrrell J.H. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br. J. Anaesth. 1971, 43:721-722.
97. Larach M.G. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth. Analg. 1989, 69:511-515.
98. Ellis F.R., Halsall P.J., Ording H., Fletcher R., Rankley E., Heffron J.J.A., Lehane M., Mortier W., Steinbereitner K., Sporn P., Theunynck D., Verburg R. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br. J. Anaesth. 1984, 56:1267-1269.
99. Larach M.G. Should we reassess the susceptibility of MH patients?. Can. J. Anaesth. 1997, 44:685-688.
100. Ording H., Brancadoro V., Cozzolino S., Ellis F.R., Glauber V., Gonano E.F., Halsall P.J., Hartung E., Heffron J.J., Heytens L., Kozak-Ribbens G., Kress H., Krivosic-Horber R., Lehmann-Horn F., Mortier W., Nivoche Y., Ranklev-Twetman E., Sigurdsson S., Snoeck M., Stieglitz P., Tegazzin V., Urwyler A., Wappler F. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol. Scand. 1997, 41:955-966.
101. Loke J.C., MacLennan D.H. Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility. Anesthesiology 1998, 88:589-600.
102. Harriman D.G. Preanesthetic investigation of malignant hyperthermia: microscopy. Int. Anesthesiol. Clin. 1979, 17:97-117.
103. Harriman D.G. Malignant hyperthermia myopathy - a critical review. Br. J. Anaesth. 1988, 60:309-316.
104. Buxton P.H. Pathology of muscle. Br. J. Anaesth. 1980, 52:139-151.
105. Reske-Nielsen E. Ultrastructure of human muscle in malignant hyperthermia. Acta Pathol. Microbiol. Scand. 1973, 81:585-587.
106. Schiller H.H., Mair W.G. Ultrastructural changes of muscle in malignant hyperthermia. J. Neurol. Sci. 1974, 21:93-100.
107. Britt B.A., Kalow W. Malignant hyperthermia: aetiology unknown. Can. Anaesth. Soc. J. 1970, 17:316-330.
108. Carpenter G.C. Rhabdomyolysis after routine administration of succinylcholine in children. Soc. Paediatr. Res. 1966, 175:29-30.
109. Hull M.T., Muller J., Albrecht W.H. Morphologic abnormalities in a case of malignant hyperthermia. Anesthesiology 1978, 48:223-228.
110. Harrison G.G., Saunders S.J., Biebuyck J.F., Hickman R., Dent D.M., Weaver V., Terblanche J. Anaesthetic-induced malignant hyperpyrexia and a method for its prediction. Br. J. Anaesth. 1969, 41:844-855.
111. Venable J.H. Skeletal muscle structure in Poland China pigs suffering from malignant hyperthermia. International Symposium on Malignant Hyperthermia, Toronto, 1971, Springfield, Illinois 1973, 208-223. R.A. Gordon, B.A. Britt, W. Kalow (Eds.).
112. Jones E.W., Nelson T.E., Anderson I.L., Kerr D.D., Burnap T.K. Malignant hyperthermia of swine. Anesthesiology 1972, 36:42-51.
113. Stadhouders A.M., Viering W.A., Verburg M.P., Ruitenbeek W., Sengers R.C. In vivo induced malignant hyperthermia in pigs. III. Localization of calcium in skeletal muscle mitochondria by means of electronmicroscopy and microprobe analysis. Acta Anaesthesiol. Scand. 1984, 28:14-26.
114. Figarella-Branger D., Kozak-Ribbens G., Rodet L., Aubert M., Borsarelli J., Cozzone P.J., Pellissier J.F. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul. Disord. 1993, 3:553-556.
115. von Breunig F., Wappler F., Hagel C., von Richthofen V., Fiege M., Weisshorn R., Stavrou D., Schulte am Esch J. Histomorphologic examination of skeletal muscle preparations does not differentiate between malignant hyperthermia-susceptible and -normal patients. Anesthesiology 2004, 100:789-794.
116. Ellis K.O., Bryant S.H. Excitation-contraction uncoupling in skeletal muscle by dantrolene sodium. Naunyn-Schmiedebergs Arch. Pharmacol. 1972, 274:107-109.
117. Ellis K.O., Castellion A.W., Honkomp L.J., Wessels F.L., Carpenter J.E., Halliday R.P. Dantrolene, a direct acting skeletal muscle relaxant. J. Pharm. Sci. 1973, 62:948-951.
118. Harrison G.G. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br. J. Anaesth. 1975, 47:62-65.
119. Britt B.A. Another view on central warehousing of dantrolene. Am. J. Hosp. Pharm. 1981, 38:464-467.
120. Harrison G.G., Chapman D.C. Dantrolene sodium in the treatment of malignant hypertension. S. Afr. Med. J. 1982, 62:503-504.
121. White M.D., Collins J.G., Denborough M.A. The effect of dantrolene on skeletal-muscle sarcoplasmic-reticulum function in malignant hyperpyrexia in pigs. Biochem. J. 1983, 212:399-405.
122. Britt B.A. Dantrolene. Can. Anaesth. Soc. J. 1984, 31:61-75.
123. Kobayashi S., Yano M., Suetomi T., Ono M., Tateishi H., Mochizuki M., Xu X., Uchinoumi H., Okuda S., Yamamoto T., Koseki N., Kyushiki H., Ikemoto N., Matsuzaki M. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 2009, 53:1993-2005.
124. 2+ release channels. Molecular mechanism and isoform selectivity. J. Biol. Chem. 2001, 276:13810-13816.
125. Paul-Pletzer K., Yamamoto T., Bhat M.B., Ma J., Ikemoto N., Jimenez L.S., Morimoto H., Williams P.G., Parness J. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J. Biol. Chem. 2002, 277:34918-34923.
126. Kobayashi S., Bannister M.L., Gangopadhyay J.P., Hamada T., Parness J., Ikemoto N. Dantrolene stabilizes domain interactions within the ryanodine receptor. J. Biol. Chem. 2005, 280:6580-6587.
127. 2+ activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia. J. Biol. Chem. 2008, 283:20813-20820.
128. Yin C.C., Blayney L.M., Lai F.A. Physical coupling between ryanodine receptor-calcium release channels. J. Mol. Biol. 2005, 349:538-546.
129. Yin C.C., D'Cruz L.G., Lai F.A. Ryanodine receptor arrays: not just a pretty pattern?. Trends Cell Biol. 2008, 18:149-156.
130. Frank M., Sleator W.W. Effects of ryanodine on a myocardial membrane vesicular fraction. Res. Commun. Chem. Pathol. Pharmacol. 1975, 11:65-72.
131. 2+ release channels with ryanodine in junctional terminal cisternae of sarcoplasmic reticulum of fast skeletal muscle. Proc. Natl Acad. Sci. USA 1985, 82:7256-7259.
132. Inui M., Saito A., Fleischer S. Purification of the ryanodine receptor and identity with feet structures of junctional terminal cisternae of sarcoplasmic reticulum from fast skeletal muscle. J. Biol. Chem. 1987, 262:1740-1747.
133. Palade P., Mitchell R.D., Fleischer S. Spontaneous calcium release from sarcoplasmic reticulum. General description and effects of calcium. J. Biol. Chem. 1983, 258:8098-8107.
134. Volpe P., Palade P., Costello B., Mitchell R.D., Fleischer S. Spontaneous calcium release from sarcoplasmic reticulum. Effect of local anesthetics. J. Biol. Chem. 1983, 258:12434-12442.
135. Mitchell R.D., Palade P., Fleischer S. Spontaneous calcium release from sarcoplasmic reticulum. Assessment of other ionic influences. J. Biol. Chem. 1984, 259:1073-1081.
136. 2+ release. J. Biol. Chem. 1987, 262:6135-6141.
137. 2+ release (SOICR). Proc. Natl Acad. Sci. USA 2004, 101:13062-13067.
138. 2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ. Res. 2005, 97:1173-1181.
139. Endo M. Calcium-induced calcium release in skeletal muscle. Physiol. Rev. 2009, 89:1153-1176.
140. 2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J. Physiol. 2009, 587:3113-3115.
141. Tanabe T., Takeshima H., Mikami A., Flockerzi V., Takahashi H., Kangawa K., Kojima M., Matsuo H., Hirose T., Numa S. Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature 1987, 328:313-318.
142. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 1990, 265:2244-2256.
143. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J. Biol. Chem. 1990, 265:13472-13483.
144. Nakai J., Imagawa T., Hakamat Y., Shigekawa M., Takeshima H., Numa S. Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel. FEBS Lett. 1990, 271:169-177.
145. MacLennan D.H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R.G., Frodis W., Britt B.A., Worton R.G. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990, 343:559-561.
146. McCarthy T.V., Healy J.M., Heffron J.J., Lehane M., Deufel T., Lehmann-Horn F., Farrall M., Johnson K. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990, 343:562-564.
147. Archibald A.L., Imlah P. The halothane sensitivity locus and its linkage relationships. Anim. Blood Groups Biochem. Genet. 1985, 16:253-263.
148. Fujii J., Otsu K., Zorzato F., de Leon S., Khanna V.K., Weiler J.E., O'Brien P.J., MacLennan D.H. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991, 253:448-451.
149. Otsu K., Khanna V.K., Archibald A.L., MacLennan D.H. Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families. Genomics 1991, 11:744-750.
150. Gillard E.F., Otsu K., Fujii J., Khanna V.K., de Leon S., Derdemezi J., Britt B.A., Duff C.L., Worton R.G., MacLennan D.H. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991, 11:751-755.
151. Durham W.J., Wehrens X.H., Sood S., Hamilton S.L. Diseases associated with altered ryanodine receptor activity. Subcell. Biochem. 2007, 45:273-321.
152. Treves S., Jungbluth H., Muntoni F., Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr. Opin. Pharmacol. 2008, 8:319-326.
153. Phillips M.S., Fujii J., Khanna V.K., DeLeon S., Yokobata K., de Jong P.J., MacLennan D.H. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 1996, 34:24-41.
154. MacLennan D.H. Discordance between phenotype and genotype in malignant hyperthermia. Curr. Opin. Neurol. 1995, 8:397-401.
155. Robinson R.L., Monnier N., Wolz W., Jung M., Reis A., Nuernberg G., Curran J.L., Monsieurs K., Stieglitz P., Heytens L., Fricker R., van Broeckhoven C., Deufel T., Hopkins P.M., Lunardi J., Mueller C.R. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum. Mol. Genet. 1997, 6:953-961.
156. Jurkat-Rott K., McCarthy T., Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000, 23:4-17.
157. McCarthy T.V., Quane K.A., Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum. Mutat. 2000, 15:410-417.
158. Brandom B.W. The genetics of malignant hyperthermia. Anesthesiol Clin. N. Am. 2005, 23:615-619. (viii).
159. Rios E., Pizarro G. Voltage sensor of excitation-contraction coupling in skeletal muscle. Physiol. Rev. 1991, 71:849-908.
160. Block B.A., Imagawa T., Campbell K.P., Franzini-Armstrong C. Structural evidence for direct interaction between the molecular components of the transverse tubule/sarcoplasmic reticulum junction in skeletal muscle. J. Cell Biol. 1988, 107:2587-2600.
161. Franzini-Armstrong C., Kish J.W. Alternate disposition of tetrads in peripheral couplings of skeletal muscle. J. Muscle Res. Cell Motil. 1995, 16:319-324.
162. Protasi F., Franzini-Armstrong C., Flucher B.E. Coordinated incorporation of skeletal muscle dihydropyridine receptors and ryanodine receptors in peripheral couplings of BC3H1 cells. J. Cell Biol. 1997, 137:859-870.
163. Weiss R.G., O'Connell K.M., Flucher B.E., Allen P.D., Grabner M., Dirksen R.T. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am. J. Physiol. Cell Physiol. 2004, 287:C1094-C1102.
164. Dainese M., Quarta M., Lyfenko A.D., Paolini C., Canato M., Reggiani C., Dirksen R.T., Protasi F. Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice. FASEB J. 2009, 23:1710-1720.
165. Wang S., Trumble W.R., Liao H., Wesson C.R., Dunker A.K., Kang C.H. Crystal structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum. Nat. Struct. Biol. 1998, 5:476-483.
166. MacLennan D.H., Reithmeier R.A. Ion tamers. Nat. Struct. Biol. 1998, 5:409-411.
167. Mulley J.C., Kozman H.M., Phillips H.A., Gedeon A.K., McCure J.A., Iles D.E., Gregg R.G., Hogan K., Couch F.J., MacLennan D.H., et al. Refined genetic localization for central core disease. Am. J. Hum. Genet. 1993, 52:398-405.
168. 2+ release channel of skeletal muscle sarcoplasmic reticulum (RyR1). Proc. Natl Acad. Sci. USA 2002, 99:16725-16730.
169. Ramachandran S., Serohijos A.W., Xu L., Meissner G., Dokholyan N.V. A structural model of the pore-forming region of the skeletal muscle ryanodine receptor (RyR1). PLoS Comput. Biol. 2009, 5:e1000367.
170. 2+ release channels (ryanodine receptors). J. Biol. Chem. 1999, 274:26120-26126.
171. Yamazawa T., Takeshima H., Shimuta M., Iino M. A region of the ryanodine receptor critical for excitation-contraction coupling in skeletal muscle. J. Biol. Chem. 1997, 272:8161-8164.
172. 2+ channels. J. Biol. Chem. 1998, 273:13403-13406.
173. 2+ channel regulation. J. Biol. Chem. 2000, 275:11618-11625.
174. Yamamoto T., Ikemoto N. Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor. Biochemistry 2002, 41:1492-1501.
175. 2+ ATPase. Nature 1989, 339:476-478.
176. 2+ ATPase of sarcoplasmic reticulum. Acta Physiol. Scand. 1992, 146:141-150.
177. 2+ ATPases. J. Biol. Chem. 1997, 272:28815-28818.
178. 2+-ATPase. Ann. NY Acad. Sci. 2003, 986:101-105.
179. 2+ ATPase of the sarcoplasmic reticulum. Annu. Rev. Biochem. 2004, 73:269-292.
180. Toyoshima C., Norimatsu Y., Iwasawa S., Tsuda T., Ogawa H. How processing of aspartylphosphate is coupled to lumenal gating of the ion pathway in the calcium pump. Proc. Natl Acad. Sci. USA 2007, 104:19831-19836.
181. Samso M., Feng W., Pessah I.N., Allen P.D. Coordinated movement of cytoplasmic and transmembrane domains of RyR upon gating. PLoS Biol. 2009, 7:e85.
182. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J. Biol. Chem. 1997, 272:26332-26339.
183. 2+ release channel function and severe central core disease. Proc. Natl Acad. Sci. USA 1999, 96:4164-4169.
184. 2+ release channels. J. Biol. Chem. 1999, 274:693-702.
185. 2+ release channel (ryanodine receptor) activity and conductance. Biophys. J. 2000, 79:828-840.
186. Avila G., O'Brien J.J., Dirksen R.T. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc. Natl Acad. Sci. USA 2001, 98:4215-4220.
187. Avila G., O'Connell K.M., Dirksen R.T. The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. J. Gen. Physiol. 2003, 121:277-286.
188. 2+ release channel function and delays development in homozygous offspring of a mutant mouse line. Proc. Natl Acad. Sci. USA 2007, 104:18537-18542.
189. 2+ release channels?. Trends Cardiovasc. Med. 2002, 12:189-197.
190. 2+ in malignant hyperthermia and central core disease. Biochem. Biophys. Res. Commun. 2004, 322:1256-1266.
191. 2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys. J. 2004, 87:3193-3204.
192. Yang T., Riehl J., Esteve E., Matthaei K.I., Goth S., Allen P.D., Pessah I.N., Lopez J.R. Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 2006, 105:1164-1175.
193. Chelu M.G., Goonasekera S.A., Durham W.J., Tang W., Lueck J.D., Riehl J., Pessah I.N., Zhang P., Bhattacharjee M.B., Dirksen R.T., Hamilton S.L. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J. 2006, 20:329-330.
194. Hernandez-Lain A., Husson I., Monnier N., Farnoux C., Brochier G., Lacene E., Beuvin M., Viou M.T., Manere L., Claeys K.G., Fardeau M., Lunardi J., Voit T., Romero N.B. de novo RYR1 heterozygous mutation (I4898T) causing lethal core-rod myopathy in twins. Eur. J. Med. Genet. 2010, (Epub ahead of print).
195. Galli L., Orrico A., Lorenzini S., Censini S., Falciani M., Covacci A., Tegazzin V., Sorrentino V. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Hum. Mutat. 2006, 27:830.
196. Ibarra M.C., Wu S., Murayama K., Minami N., Ichihara Y., Kikuchi H., Noguchi S., Hayashi Y.K., Ochiai R., Nishino I. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006, 104:1146-1154.
197. Carpenter D., Robinson R.L., Quinnell R.J., Ringrose C., Hogg M., Casson F., Booms P., Iles D.E., Halsall P.J., Steele D.S., Shaw M.A., Hopkins P.M. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br. J. Anaesth. 2009, 103:538-548.
198. Girard T., Suhner M., Levano S., Singer M., Zollinger A., Hofer C.K. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor gene mutation p.Tyr522Ser. Anesth. Analg. 2008, 107:1953-1955.
199. Durham W.J., Aracena-Parks P., Long C., Rossi A.E., Goonasekera S.A., Boncompagni S., Galvan D.L., Gilman C.P., Baker M.R., Shirokova N., Protasi F., Dirksen R., Hamilton S.L. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008, 133:53-65.
200. 2+ release in muscle fibers of Y522S RyR1 knock-in mice. Proc. Natl Acad. Sci. USA 2009, 106:4531-4536.
201. 2+ entry, release, and retrograde signaling to the DHPR. J. Gen. Physiol. 2010, 135:619-628.
202. Bannister R.A., Esteve E., Eltit J.M., Pessah I.N., Allen P.D., Lopez J.R., Beam K.G. A malignant hyperthermia-inducing mutation in RYR1 (R163C): consequent alterations in the functional properties of DHPR channels. J. Gen. Physiol. 2010, 135:629-640.
203. Boncompagni S., Rossi A.E., Micaroni M., Hamilton S.L., Dirksen R.T., Franzini-Armstrong C., Protasi F. Characterization and temporal development of cores in a mouse model of malignant hyperthermia. Proc. Natl Acad. Sci. USA 2009, 106:21996-22001.
204. I4895T/wt mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc. Natl Acad. Sci. USA 2009, 106:21813-21818.
205. Vallat J.M., de Lumley L., Loubet A., Leboutet M.J., Corvisier N., Umdenstock R. Coexistence of minicores, cores, and rods in the same muscle biopsy. A new example of mixed congenital myopathy. Acta Neuropathol. 1982, 58:229-232.
206. Monnier N., Marty I., Faure J., Castiglioni C., Desnuelle C., Sacconi S., Estournet B., Ferreiro A., Romero N., Laquerriere A., Lazaro L., Martin J.J., Morava E., Rossi A., Van der Kooi A., de Visser M., Verschuuren C., Lunardi J. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum. Mutat. 2008, 29:670-678.
207. Morgan-Hughes J.A., Brett E.M., Lake B.D., Tome F.M. Central core disease or not? Observations on a family with a non-progressive myopathy. Brain 1973, 96:527-536.
208. Dubowitz V., Roy S. Central core disease of muscle: clinical, histochemical and electron microscopic studies of an affected mother and child. Brain 1970, 93:133-146.
209. Sewry C.A., Muller C., Davis M., Dwyer J.S., Dove J., Evans G., Schroder R., Furst D., Helliwell T., Laing N., Quinlivan R.C. The spectrum of pathology in central core disease. Neuromuscul. Disord. 2002, 12:930-938.
210. Bethlem J., Arts W.F., Dingemans K.P. Common origin of rods, cores, miniature cores, and focal loss of cross-striations. Arch. Neurol. 1978, 35:555-566.
211. Protasi F., Paolini C., Dainese M. Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke. J. Physiol. 2009, 587:3095-3100.
212. Laitinen P.J., Swan H., Piippo K., Viitasalo M., Toivonen L., Kontula K. Genes, exercise and sudden death: molecular basis of familial catecholaminergic polymorphic ventricular tachycardia. Ann. Med. 2004, 36(Suppl. 1):81-86.
213. Wehrens X.H. The molecular basis of catecholaminergic polymorphic ventricular tachycardia: what are the different hypotheses regarding mechanisms?. Heart Rhythm 2007, 4:794-797.
214. Venetucci L.A., Trafford A.W., O'Neill S.C., Eisner D.A. The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc. Res. 2008, 77:285-292.
215. Liu N., Ruan Y., Priori S.G. Catecholaminergic polymorphic ventricular tachycardia. Prog. Cardiovasc. Dis. 2008, 51:23-30.
216. Uchinoumi H., Yano M., Suetomi T., Ono M., Xu X., Tateishi H., Oda T., Okuda S., Doi M., Kobayashi S., Yamamoto T., Ikeda Y., Ohkusa T., Ikemoto N., Matsuzaki M. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ. Res. 2010, 106:1413-1424.
217. Nelson T.E. Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J. Clin. Invest. 1983, 72:862-870.
218. 2+ release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics. Anesthesiology 1988, 69:571-577.
219. 2+ release. FEBS Lett. 1990, 263:292-294.
220. 2+. Biophys. J. 2007, 92:2757-2770.
221. 2+ release. Biochem. J. 2008, 412:171-178.
222. Nelson T.E., Flewellen E.H., Gloyna D.F. Spectrum of susceptibility to malignant hyperthermia - diagnostic dilemma. Anesth. Analg. 1983, 62:545-552.
223. ++ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. J. Pharmacol. Exp. Ther. 1991, 256:645-649.
224. Kim E., Youn B., Kemper L., Campbell C., Milting H., Varsanyi M., Kang C. Characterization of human cardiac calsequestrin and its deleterious mutants. J. Mol. Biol. 2007, 373:1047-1057.
225. Guo W., Campbell K.P. Association of triadin with the ryanodine receptor and calsequestrin in the lumen of the sarcoplasmic reticulum. J. Biol. Chem. 1995, 270:9027-9030.
226. Guo W., Jorgensen A.O., Campbell K.P. Triadin, a linker for calsequestrin and the ryanodine receptor. Soc. Gen. Physiol. Ser. 1996, 51:19-28.
227. Royer L., Rios E. Deconstructing calsequestrin. Complex buffering in the calcium store of skeletal muscle. J. Physiol. 2009, 587:3101-3111.
228. Beard N.A., Laver D.R., Dulhunty A.F. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Prog. Biophys. Mol. Biol. 2004, 85:33-69.
229. 2+ regulation. J. Biol. Chem. 2003, 278:16176-16182.
230. Bal N.C., Sharon A., Gupta S.C., Jena N., Shaikh S., Gyorke S., Periasamy M. The catecholaminergic polymorphic ventricular tachycardia mutation R33Q disrupts the N-terminal structural motif that regulates reversible calsequestrin polymerization. J. Biol. Chem. 2010, 285:17188-17196.
231. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 2003, 4:566-577.
232. Nelson T.E. Halothane effects on human malignant hyperthermia skeletal muscle single calcium-release channels in planar lipid bilayers. Anesthesiology 1992, 76:588-595.
233. 2+ release channels of pigs heterozygous for malignant hyperthermia. Muscle Nerve 1995, 18:1167-1176.
234. 2+ regulation defects. Physiol. Rev. 1996, 76:537-592.
235. Xu L., Wang Y., Yamaguchi N., Pasek D.A., Meissner G. Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies. J. Biol. Chem. 2008, 283:6321-6329.
236. 2+ ion permeation and release from the sarcoplasmic reticulum. J. Gen. Physiol. 2011, 137:43-57.
237. Priori S.G., Chen S.R.W. Inherited dysfunction of sarcoplasmic reticulum calcium handling and arrhythmogenesis. Circ. Res. 2011, 108:871-883.